Back to top
more

Edwards Lifesciences (EW)

(Real Time Quote from BATS)

$78.68 USD

78.68
2,821,748

-0.56 (-0.71%)

Updated Aug 6, 2025 03:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Abbott-North West London Pathology Expand in Diagnostics

by Zacks Equity Research

Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.

    Zacks Equity Research

    Intuitive Surgical at 52-Week High: What's Driving the Stock?

    by Zacks Equity Research

    Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.

      Zacks Equity Research

      Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study

      by Zacks Equity Research

      Medtronic (MDT) announces a clinical trial to evaluate one-month dual antiplatelet therapy in patients implanted with the Resolute Onyx Drug-Eluting Stent during PCI procedures.

        Zacks Equity Research

        Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish

        by Zacks Equity Research

        Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.

          Zacks Equity Research

          Varian (VAR) Rides on Oncology and Proton Therapy Businesses

          by Zacks Equity Research

          Varian Medical's (VAR) oncology and Proton therapy business' growth prospects remain impressive. However, competition in the radiotherapy space raise concern.

            Zacks Equity Research

            Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss

            by Zacks Equity Research

            Civitas Solutions (CIVI) gains on strength in Post-Acute Specialty Rehabilitation Services and Adult Day Health services in Q3. However, tweaked full-year 2017 guidance signals dull prospects.

              Zacks Equity Research

              Myriad Genetics (MYGN) Grows on Higher Cancer Test Volumes

              by Zacks Equity Research

              Myriad Genetics (MYGN) rides high on strength in Molecular Diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

                Zacks Equity Research

                STERIS (STE) Banks on Organic Growth, Competition Intense

                by Zacks Equity Research

                STERIS' (STE) cost structure is likely to be enhanced through recent organizational changes.

                  Zacks Equity Research

                  BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife

                  by Zacks Equity Research

                  The company achieved annualized supply chain improvement since the acquisition of Home Solutions.

                    Zacks Equity Research

                    OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2

                    by Zacks Equity Research

                    OPKO Health (OPK) posted lackluster Q2 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.

                      Zacks Equity Research

                      CVS Health Grows on Specialty Pharmacy amid Retail Woes

                      by Zacks Equity Research

                      CVS Health (CVS) rides on strong PBM selling season. Poor Retail/ LTC business and escalating expenses are drag on the bottom line.

                        Zacks Equity Research

                        Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down

                        by Zacks Equity Research

                        Chimerix (CMRX) revenues in Q2 were hurt by reduced reimbursable expenses related to the company's BARDA developmental contract.

                          Zacks Equity Research

                          Haemonetics Banks on Solid Plasma & Haemonetics Management

                          by Zacks Equity Research

                          Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).

                            Zacks Equity Research

                            Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4

                            by Zacks Equity Research

                            Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.

                              Zacks Equity Research

                              Nevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat

                              by Zacks Equity Research

                              Nevro's (NVRO) topline gains on continued global adoption of HF10 therapy. Rising operating expenses are major concerns.

                                Zacks Equity Research

                                STERIS (STE) Beats on Q1 Earnings & Revenues, Margins Up

                                by Zacks Equity Research

                                STERIS' (STE) organic growth performance was strong across most segments in Q1. Robust cash position was another upside.

                                  Zacks Equity Research

                                  BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss

                                  by Zacks Equity Research

                                  BioScrip (BIOS) continues to disappoint in Q2 mainly due to its strategic shift to focus on growing its core revenue mix.

                                    Zacks Equity Research

                                    BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates

                                    by Zacks Equity Research

                                    BioTelemetry (BEAT) rides high on all its segments in Q2. The company is also putting in efforts in product innovation through research and development.

                                      Zacks Equity Research

                                      Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues

                                      by Zacks Equity Research

                                      Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

                                        Zacks Equity Research

                                        Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2

                                        by Zacks Equity Research

                                        Penumbra (PEN) witnessed strong growth across all its geographies and product lines in Q2. New product launches raise hope.

                                          Zacks Equity Research

                                          C.R. Bard Shareholders Approve Merger With Becton, Dickinson

                                          by Zacks Equity Research

                                          C. R. Bard, Inc. (BCR) announced that the majority of its shareholders have approved its merger with Becton, Dickinson and Company (BDX).

                                            Zacks Equity Research

                                            CVS Health (CVS) Q2 Earnings Beat, '17 Guidance Narrowed

                                            by Zacks Equity Research

                                            CVS Health continues to grow (CVS) with Pharmacy Services business. However, its Retail/LTC sales drop.

                                              Zacks Equity Research

                                              Henry Schein (HSIC) Q2 Earnings & Revenues Beat, View Intact

                                              by Zacks Equity Research

                                              Henry Schein (HSIC) maintained its stellar performance in Q2 as well, courtesy of strength in all of its business segments.

                                                Zacks Equity Research

                                                Orthofix (OFIX) Earnings Meet, Sales Beat Estimates in Q2

                                                by Zacks Equity Research

                                                Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation businesses. Moreover, raised full-year 2017 guidance buoys optimism.

                                                  Zacks Equity Research

                                                  Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates

                                                  by Zacks Equity Research

                                                  Haemonetics (HAE) rides high on Plasma and Haemonetics Management franchises strength in Q1.